Get started
Author

Aimee D Shu

Observed names: A Shu, A. Shu, A.D. Shu, AIMEE D. SHU, Aimee D. Shu, Aimee D. Shu, Aimee Der-Huey Shu, Aimee Shu, Shu, Aimee D.
Observed institutions: Brigham and Women's Hospital, Palo Alto Medical Foundation, Palo Alto Networks (United States), Ascendis Pharma (Denmark), Stanford Medicine, VMware (United States), Columbia University, Stanford University
ORCID: 0000-0003-1801-5289
Observed ORCID: 0000-0003-1801-5289
OpenAlex ID: A5035620014
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
2020 · Aliya A Khan, Mishaela R Rubin, et al. · Journal of Bone and Mineral Research · 112
PDF
Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
2021 · Paul S Thornton, Aristides K Maniatis, et al. · The Journal of Clinical Endocrinology & Metabolism · 89
PDF
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
2021 · Aliya A Khan, Lars Rejnmark, et al. · The Journal of Clinical Endocrinology & Metabolism · 76
PDF
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
2024 · Bart L Clarke, Aliya A Khan, et al. · The Journal of Clinical Endocrinology & Metabolism · 45
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
2024 · Lars Rejnmark, Elvira O. Gosmanova, et al. · Advances in Therapy · 44
Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial.
2009 · Aimee Der-Huey Shu, Margaret R Stedman, et al. · PubMed · 44
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
2022 · Aristides K Maniatis, Samuel J Casella, et al. · The Journal of Clinical Endocrinology & Metabolism · 31
Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US
2016 · Sun Moon Kim, Aimee D. Shu, et al. · PLoS ONE · 30
PDF
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
2023 · Ravi Savarirayan, Daniel G. Hoernschemeyer, et al. · EClinicalMedicine · 28
PDF
Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
2022 · Aristides K. Maniatis, Ulhas Nadgir, et al. · Hormone Research in Paediatrics · 21
Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency
2021 · Zhengning Lin, Aimee D Shu, et al. · Journal of the Endocrine Society · 21
PDF
Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES)
2021 · Meryl Brod, Lori McLeod, et al. · Journal of Patient-Reported Outcomes · 17
PDF
Once-Weekly Navepegritide in Children With Achondroplasia
2025 · Ravi Savarirayan, Ciara McDonnell, et al. · Archives of Pediatrics and Adolescent Medicine · 12
PDF
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
2025 · Aristides K. Maniatis, Paul S. Thornton, et al. · Hormone Research in Paediatrics · 10
Quality of life and hypertension after hormone therapy withdrawal in New York City
2013 · Michelle P. Warren, Olivia Richardson, et al. · Menopause The Journal of The North American Menopause Society · 8
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial
2026 · Mishaela R Rubin, Bart L Clarke, et al. · Journal of Bone and Mineral Research · 7
OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
2019 · Paul Thornton, Paul Hofman, et al. · Journal of the Endocrine Society · 7
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension
2025 · Mishaela Rubin, Andrea Palermo, et al. · The Journal of Clinical Endocrinology & Metabolism · 3
PDF
Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
2021 · Aristides K Maniatis, Samuel J Casella, et al. · Journal of the Endocrine Society · 3
PDF
OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
2020 · Aristides K Maniatis, Ulhas Nadgir, et al. · Journal of the Endocrine Society · 3
PDF
Longitudinal Observation of Children with Achondroplasia: Findings from a Global Natural History Study (ACHieve)
2026 · Ciara McDonnell, Hanne Buciek Hove, et al. · Hormone Research in Paediatrics · 2
PDF
12542 Results Of The Foresight Trial Support The Efficacy And Safety Of Once-weekly Lonapegsomatropin In Adults With Growth Hormone Deficiency (ghd)
2024 · Beverly Mk Biller, Aleksandra Gilis-Januszewska, et al. · Journal of the Endocrine Society · 2
PDF
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial
2024 · Peter Schwarz, Lars Rejnmark, et al. · Endocrine Abstracts · 2
OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
2023 · Bart Clarke, Aliya Aziz Khan, et al. · Journal of the Endocrine Society · 2
PDF
OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
2022 · Intekhab Ahmed, Erik Eriksen, et al. · Journal of the Endocrine Society · 2
PDF
Works count: 73
Citation count: 635
H-index: 12
I10-index: 14
Year
Topic
Type